NHS Greater Glasgow and Clyde: New Medicines Decisions

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHSScotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within NHS Greater Glasgow and Clyde (NHSGG&C) because of available services and prefere

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The Greater Glasgow and Clyde ADTC is responsible for advising the NHSGG&C health board on all aspects of the use of medicines.

Medicines routinely available within NHSGG&C are usually included in the GGC Formulary. The Formulary is a list of medicines for use in the health board that has been agreed by ADTC in consultatior medicines for healthcare professionals to prescribe for common medical conditions. The GGC Formulary can help improve safety as prescribers are likely to become more familiar with the medicines in are consistent across the health board.

How does NHSGG&C decide which new medicines to make routinely available for patients?

The ADTC in NHSGG&C will consider national and local guidance before deciding whether to make a new medicine routinely available.

What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland
    - how well the medicine works,
    - which patients might benefit from it ,
    - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
    - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health a Appraisals (NICE MTAs) are applicable in Scotland.

What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in NHSGG&C.

Why is a particular medicine not routinely available in NHSGGC?

- This is usually because the medicine is not recommended for use in NHSScotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences in which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

Medicine	Condition being treated	NHSGGC Decision	Date of decision

alectinib Alecensa® SMC2749	Monotherapy as adjuvant treatment for adult patients with Stage IB (tumours ≥ 4 cm) to IIIA (7th edition of the UICC/AJCC-staging system) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) following complete tumour resection.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/06/2025	28/04/2025
amivantamab Rybrevant® SMC2768	In combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).	Not routinely available as not recommended for use in NHSScotland	28/04/2025
anastrazole NCMAG113	primary prevention of breast cancer in post-menopausal people at moderate or high risk	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 25/08/2025	28/04/2025
atezolizumab Tecentriq® SMC2769	Monotherapy for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy	Not routinely available as not recommended for use in NHSScotland	28/04/2025
axicabtagene ciloleucel Yescarta® SMC2695	Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/06/2025	28/04/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
bimekizumab Bimzelx® SMC2698	Treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.	Routinely available in line with local or regional guidance	28/04/2025
cabozantinib SMC2754	Monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/06/2025	28/04/2025
cemiplimab Libtayo® SMC2719	monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.	Routinely available in line with local or regional guidance	28/04/2025
crovalimab Piasky® SMC2728	Monotherapy for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH): - In patients with haemolysis with clinical symptom(s) indicative of high disease activity. - In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months.	Routinely available in line with national guidance	28/04/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
danicopan Voydeya® SMC2675	Add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia.	Routinely available in line with national guidance	28/04/2025
dapagliflozin Forxiga® SMC2763	Treatment of chronic kidney disease (CKD).	Routinely available in line with local or regional guidance	28/04/2025
durvalumab Imfinzi® SMC2734	In combination with etoposide and either carboplatin or cisplatin for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/06/2025	28/04/2025
elafibranor Iqirvo® SMC2714	Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.	Routinely available in line with local or regional guidance	28/04/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
elranatamab Elrexfio® SMC2669	Monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.	Routinely available in line with local or regional guidance	28/04/2025
eplontersen Wainzua® SMC2755	Treatment of hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) in adult patients with Stage 1 and 2 polyneuropathy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/06/2025	28/04/2025
etranacogene dezaparvovec Hemgenix® SMC2649	treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/06/2025	28/04/2025
futibatinib Lytgobi® SMC2661	Monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/06/2025	28/04/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
iptacopan Fabhalta® SMC2676	Monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.	Routinely available in line with national guidance	28/04/2025
lebrikizumab Ebglyss® SMC2707	Treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.	Routinely available in line with local or regional guidance	28/04/2025
linzagolix Yselty® SMC2631	Treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.	Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative	28/04/2025
mavacamten Camzyos® SMC2618	Treatment of symptomatic (New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/06/2025	28/04/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Nivolumab, ipilimumab NCMAG121	Nivolumab in combination with ipilimumab for the neoadjuvant treatment of resectable stage III melanoma	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/06/2025	28/04/2025
olaparib Lynparza® SMC2737	Monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.	Routinely available in line with local or regional guidance	28/04/2025
pegunigalsidase alfa Elfabrio® SMC2665	for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/06/2025	28/04/2025
pembrolizumab Keytruda SMC 2689	As monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy.	Routinely available in line with local or regional guidance	28/04/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
pembrolizumab NCMAG122	For the neoadjuvant treatment of stage IIIB to IIID or oligometastatic resectable stage IV melanoma	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/06/2025	28/04/2025
pembrolizumab Keytruda® SMC2660	in combination with fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express programmed death-ligand 1 (PD-L1) with a combined positive score (CPS) ≥ 1.	Routinely available in line with local or regional guidance	28/04/2025
Pomalidomide in combination with bortezomib and dexamethasone NCMAG120	Treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide	Routinely available in line with local or regional guidance	28/04/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Pomalidomide in combination with dexamethasone NCMAG119	Treatment of adult patients with multiple myeloma who have received one prior treatment regimen including lenalidomide, and where more effective alternatives are not suitable.	Routinely available in line with local or regional guidance	28/04/2025
quizartinib Vanflyta® SMC2699	In combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive.	Routinely available in line with local or regional guidance	28/04/2025
raloxifene NCMAG114	Primary prevention of breast cancer in post-menopausal people at moderate or high risk who are not suitable for on-label alternatives.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 25/08/2025	28/04/2025
Relugolix Orgovyx SMC 2678	•For the treatment of adult patients with advanced hormone-sensitive prostate cancer •for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy •as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer	Routinely available in line with local or regional guidance	28/04/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
ripretinib Qinlock® SMC2722	Treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.	Not routinely available as not recommended for use in NHSScotland	28/04/2025
Semaglutide Wegovy SMC2497	An adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of •≥30kg/m2 (obesity), or •≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/06/2025	28/04/2025
spesolimab Spevigo® SMC2729	Treatment of flares in adult patients with generalised pustular psoriasis (GPP) as monotherapy.	Not routinely available as not recommended for use in NHSScotland	28/04/2025
talazoparib Talzenna® SMC2753	In combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/06/2025	28/04/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
tamoxifen NCMAG115	Primary prevention of breast cancer in people at moderate or high risk	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 25/08/2025	28/04/2025
tebentafusp Kimmtrak® SMC2746	Monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.	Not routinely available as not recommended for use in NHSScotland	28/04/2025
teclistamab Tecvayli® SMC2668	Monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.	Routinely available in line with local or regional guidance	28/04/2025
tirzepatide Mounjaro® SMC2653	For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/06/2025	28/04/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
vibegron Obgemsa® SMC2696	Symptomatic treatment of adult patients with overactive bladder (OAB) syndrome.	Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative	28/04/2025
zanubrutinib Brukinsa® SMC2684	Monotherapy for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.	Routinely available in line with local or regional guidance	28/04/2025